Arovella Therapeutics Ltd - Asset Resilience Ratio

Latest as of December 2025: 95.65%

Arovella Therapeutics Ltd (ALA) has an Asset Resilience Ratio of 95.65% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$19.37 Million
≈ $13.70 Million USD Cash + Short-term Investments

Total Assets

AU$20.25 Million
≈ $14.33 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2006–2025)

This chart shows how Arovella Therapeutics Ltd's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Arovella Therapeutics Ltd to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Arovella Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Arovella Therapeutics Ltd market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$19.37 Million 95.65%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$19.37 Million 95.65%

Asset Resilience Insights

  • Very High Liquidity: Arovella Therapeutics Ltd maintains exceptional liquid asset reserves at 95.65% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Arovella Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Arovella Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 10.93%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 57.90%
TELIX Pharmaceuticals Ltd
AU:TLX
Biotechnology 32.29%
Inner Mongolia Furui Med Sci
SHE:300049
Biotechnology 2.34%
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Biotechnology 39.07%
Damora Therapeutics, Inc.
NASDAQ:DMRA
Biotechnology 0.00%

Annual Asset Resilience Ratio for Arovella Therapeutics Ltd (2006–2025)

The table below shows the annual Asset Resilience Ratio data for Arovella Therapeutics Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 96.65% AU$20.88 Million
≈ $14.77 Million
AU$21.60 Million
≈ $15.28 Million
+0.95pp
2024-06-30 95.71% AU$12.71 Million
≈ $9.00 Million
AU$13.28 Million
≈ $9.40 Million
+1.11pp
2023-06-30 94.60% AU$5.18 Million
≈ $3.66 Million
AU$5.47 Million
≈ $3.87 Million
+28.70pp
2022-06-30 65.90% AU$6.07 Million
≈ $4.30 Million
AU$9.21 Million
≈ $6.52 Million
+3.05pp
2021-06-30 62.85% AU$6.72 Million
≈ $4.75 Million
AU$10.69 Million
≈ $7.56 Million
+48.28pp
2020-06-30 14.57% AU$977.47K
≈ $691.62K
AU$6.71 Million
≈ $4.75 Million
-11.97pp
2019-06-30 26.54% AU$4.31 Million
≈ $3.05 Million
AU$16.25 Million
≈ $11.50 Million
+25.95pp
2018-06-30 0.59% AU$98.13K
≈ $69.43K
AU$16.64 Million
≈ $11.78 Million
-8.25pp
2017-06-30 8.84% AU$1.77 Million
≈ $1.25 Million
AU$20.02 Million
≈ $14.16 Million
+8.13pp
2009-06-30 0.71% AU$118.52K
≈ $83.86K
AU$16.61 Million
≈ $11.75 Million
-0.01pp
2008-06-30 0.73% AU$116.62K
≈ $82.52K
AU$16.06 Million
≈ $11.37 Million
-8.25pp
2007-06-30 8.98% AU$1.89 Million
≈ $1.33 Million
AU$21.00 Million
≈ $14.86 Million
+1.64pp
2006-06-30 7.34% AU$1.22 Million
≈ $863.57K
AU$16.63 Million
≈ $11.77 Million
--
pp = percentage points

About Arovella Therapeutics Ltd

AU:ALA Australia Biotechnology
Market Cap
$50.46 Million
AU$71.32 Million AUD
Market Cap Rank
#21870 Global
#767 in Australia
Share Price
AU$0.06
Change (1 day)
-1.67%
52-Week Range
AU$0.06 - AU$0.11
All Time High
AU$0.57
About

Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, … Read more